We decided to stratify patients according to renal and neurological involvement in order to investigate IL-23 and IL-27 in the patients with the highest SLE activity in the respective organs, thereby identifying the highest risk of damage. This evidence concerns the gene IL37 and systemic lupus erythematosus.